Amneal has reported a “solid” set of results for 2022, driving sales up by 6% to $2.21bn as it continues to move into more complex generics and kicks off in earnest its ambitions in biosimilars.
Citing growth from new generics launches as well as the expansion of its AvKare business (Also see "Amneal Takes...






